Moderna Announces $2 Billion Zero-Coupon Convertible Debt Offering
Moderna (NASDAQ:MRNA) has announced a proposed private placement of $2 billion in zero-coupon convertible senior notes due in 2032, with an option for underwriters to purchase up to an additional $300 million. The offering is intended to provide capital without regular interest payments and will be used partly to fund capped-call transactions aimed at mitigating dilution from potential conversions into common stock. The company recently reported positive Phase 3 trial results for its intismeran autogene in combination with pembrolizumab, meeting key endpoints. This clinical success strengthens Moderna’s oncology investment case and provides a more solid foundation than an early-stage pipeline would offer. However, the zero-coupon structure means that part of the proceeds will be used to pay premiums for capped calls rather than directly funding research or commercialization. The offering includes risk management features such as a cap price expected to be at least 150% above the stock price at pricing. While this may limit dilution within a defined range, it does not eliminate all risks—especially if Moderna’s stock appreciates beyond that threshold.
Tickers: $MRNA